A-1331852 is an orally available BCL-XL selective inhibitor with a Ki of less than 10 pM.
IC50&Target
Bcl-xL
0.01 nM (Ki)
Bcl-W
4 nM (Ki)
Bcl-2
6 nM (Ki)
Mcl-1
142 nM (Ki)
体外研究
A-1331852 selectively disrupts BCL-XL–BIM complexes and induces the hallmarks of apoptosis in BCL-XL–dependent Molt-4 cells with IC50s in the low nanomolar range but does not affect MEF cells lacking BAK or BAX. In CellTiter-Glo cell viability assay, A-1331852 inhibits NCI-H847, NCI-H1417, SET-2, HEL, OCI-M2 with EC50 values of 3, 7, 80, 120 and 100 nM.
体内研究
A-1331852 demonstrates antitumor efficacy in the Molt-4 xenograft model, inducing tumor regressions as a single agent. Additionally, A-1331852 combines with venetoclax to recapitulate the efficacy of navitoclax in the NCI-H1963.FP5 xenograft model of SCLC. A-1331852 significantly inhibits tumor growth in seven subcutaneous xenograft models of solid tumors, including breast cancer, NSCLC, and ovarian cancer.
分子式
C38H38N6O3S
分子量
658.81
CAS号
1430844-80-6
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder
-20°C
3 years
4°C
2 years
In solvent
-80°C
6 months
-20°C
1 month
溶解性数据
In Vitro:
DMSO : ≥ 50 mg/mL (75.89 mM)
Ethanol : 4 mg/mL (6.07 mM; ultrasonic and warming and heat to 60°C)
H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 80°C) (insoluble)